1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Drug News 23 NOVEMBER 2015

Cancer Drug News 23 NOVEMBER 2015

  • November 2015
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - Pfizer Laying Strong Foundations For Long-Term Oncology Growth
Industry Brief - Kadcyla Price Remains Too High For NICE
Industry Brief - Kyprolis Gains EU Approval For Combination Use In Relapsed MM
Industry Trend Analysis - Crowded MM Market Will Provide Challenge For Ninlaro
Industry Brief - FDA Grants ODD To Marizomib In Malignant Glioma
Industry Brief - ZAI Lab/Hanmi Sign Chinese Licensing Deal To Develop EGFr-Targeted LC Therapy
Industry Brief - Xalkori Significantly Prolongs PFS In East Asian Phase III Study For ALK-Positive NSCLC
Industry Trend Analysis - Clovis Rociletinib Slip Solidifies AstraZeneca's Position
Industry Trend Analysis - CDx Evolving With Increased Precision Medicine Focus
Industry Brief - FDA Accepts For Priority Review Opdivo sBLA In RCC
Industry Brief - Morphotek Signs Radioimmunotherapy Pact With University Of Gothenburg
Industry Brief - Chugai Receives Japanese Approval For Additional Xeloda Indication
Industry Brief - Threshold/Merck KGaA Enter Evofosfamide Co-Promotion Agreement
Industry Brief - Tafinlar+Mekinist Receives Regular FDA Approval For MM
Industry Brief - FDA Grants Breakthrough Therapy Designation To Avelumab For MCC
Industry Brief - Sandoz' Third Biosimilar Application Accepted By The FDA
Industry Brief - Cancer Conferences - February 2016

Table Of Contents

Cancer Drug News 23 NOVEMBER 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Lung Cancer: Analytical Tool

August 2016 $ 8096

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.